| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1876887 | Applied Radiation and Isotopes | 2009 | 4 Pages |
Abstract
BNCT causes selective damage to tumor cells by neutron capture reactions releasing high LET-particles where 10B-atoms are present. Neither the 10B-compound nor thermal neutrons alone have any therapeutic effect. Therefore, the development of BNCT to a treatment modality needs strategies, which differ from the standard phase I–III clinical trials. An innovative trial design was developed including translational research and a phase I aspect. The trial investigates as surrogate endpoint BSH and BPA uptake in different tumor entities.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
A. Wittig, L. Collette, R. Moss, W.A. Sauerwein,